Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
- DOI
- 10.3389/fonc.2022.918855
- Published
- 2022-07-25
- Container
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2022.918855,
title = {Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report},
author = {Pascal Wang and Emmanuelle Fabre and Antoine Martin and Kader Chouahnia and Ambre Benabadji and Lise Matton and Boris Duchemann},
year = {2022},
journal = {Frontiers in Oncology},
doi = {10.3389/fonc.2022.918855},
url = {https://doi.org/10.3389/fonc.2022.918855}
}RIS
TY - JOUR TI - Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report AU - Pascal Wang AU - Emmanuelle Fabre AU - Antoine Martin AU - Kader Chouahnia AU - Ambre Benabadji AU - Lise Matton AU - Boris Duchemann PY - 2022 JO - Frontiers in Oncology DO - 10.3389/fonc.2022.918855 UR - https://doi.org/10.3389/fonc.2022.918855 ER -
APA
Wang, P., Fabre, E., Martin, A., Chouahnia, K., Benabadji, A., Matton, L., & Duchemann, B. (2022). Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report. Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.918855
Source records
- crossref · retrieved 2026-09-25T05:29:39.865Z